IP Library Granted Patent US 11,958,882
Granted Patent B2
US 11,958,882 · App. 16/494,165 · Granted Apr 16, 2024

Methods directed to crystalline biomolecules

Inventors: Rizwan Sharnez (Mead, CO); William Trieu (Agoura Hills, CA); Marc A. Caporini (Cambridge, MA); Ron C. Kelly (Thousand Oaks, CA); Neill Burt (Denver, CO); Laura Nicholson (Boulder, CO); Twinkle R. Christian (Thousand Oaks, CA)
Assignee: AMGEN INC.
C07K1/306A61K39/39591B01J8/20B01J8/38C30B7/00C30B7/10C30B30/04G01N24/087C30B30/00C30B30/02G01N24/00G01N24/008G01R33/20G01R33/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,958,882
App. No.
16/494,165
Granted
Apr 16, 2024
Kind
B2
Abstract

Disclosed herein are methods of preparing a composition comprising crystalline biomolecules, for example, crystalline antibodies. In exemplary embodiments, the method comprises forming a fluidized bed of crystalline biomolecules using, for example, a counter-flow centrifuge to exchange buffer and/or to concentrate the crystalline biomolecules in a solution. Also provided are methods of detecting crystalline biomolecules and/or amorphous biomolecules in a sample.

Claims (16)

1. A method of preparing a composition comprising crystalline biomolecules, comprising:

a) forming a fluidized bed of crystalline biomolecules in a rotating chamber comprising an inlet and an outlet, wherein the fluidized bed is created by rotating the chamber about a substantially horizontal axis to create a centrifugal force (F centrifugal ) in said chamber, flowing a first stream of a first solution through the inlet in a direction opposite to the direction of the F centrifugal and at a first flow rate (FR1) having a force (F FR1 ) which counter balances F centrifugal , and collecting the first solution from the chamber while substantially maintaining the formation of the fluidized bed of crystallized biomolecules;

b) performing step (i), (ii), or (iii):

i. flowing a second stream of a second solution to replace the first stream of the first solution while substantially maintaining the formation of the fluidized bed of crystallized biomolecules;

ii. concentrating the crystallized biomolecules within a region of the chamber by changing FR1 to a second flow rate (FR2) having a force (F FR2 ) which is less than F centrifugal or by increasing the speed of rotation of the chamber to increase F centrifugal to a level which is greater than F FR1 ;

iii. a combination of step (i) and step (ii); and

c) flowing a second stream into the chamber through the outlet in a direction which is parallel to the direction of the F centrifugal to crystalline remove the crystalline biomolecules from the chamber.

2. The method of claim 1 , wherein F centrifugal is 1000 g during at least step (i).

3. The method of claim 1 , wherein the feed volume of the second stream of the second solution is about 50 to about 500 ml during step (i).

4. The method of claim 1 , wherein (A) the number of volumes of the first solution per chamber is 2 or more during step (i), (B) FR1 is about 50 ml/min to about 150 ml/min during step (i), (C) the first solution is a hypertonic crystallization buffer, (D) the second solution is an isotonic formulation buffer, (E) the second solution is an isotonic formulation buffer, (F) the F centrifugal is 1000 g during step (ii), (F) the feed volume of the second stream of the second solution is about 100 to about 500 ml during step (ii), (G) the number of volumes of the first solution per chamber is 1 or 2 during step (ii), (H) FR2 is about 10 ml/min to about 50 ml/min during step (ii), (I) the concentration of the crystalline biomolecules is increased at least 2-fold, (J) the method comprises decreasing F centrifugal to a level of about 5 g and about 20 g, (K) FR1 is controlled by a first pump and the first pump is set to about 10 ml/min to about 100 ml/min after step (b), (L) the rotating chamber is connected to a chamber peristaltic pump, (M) the method is carried out in an apparatus comprising more than one rotating chamber, (N) the crystalline biomolecule is a protein or comprises one or more polypeptide chains, or (O) any combination thereof.

5. The method of claim 4 , wherein the concentration of the crystalline biomolecules is increased at least 3-fold or at least 4-fold.

6. The method of claim 4 , wherein the chamber peristaltic pump is set to pump in the same direction of the first pump and F centrifugal .

7. The method of claim 4 , wherein the chamber peristaltic pump is set to about 75 ml/min, the first pump is set to about 50 ml/min, and F centrifugal is decreased to below 10 g.

8. The method of claim 4 , wherein the apparatus comprises at least 2, at least 4 or at least 6 rotating chambers.

9. The method of claim 8 , wherein steps (a) to (c) are carried out in more than one chamber.

10. The method of claim 9 , wherein crystalline biomolecules are removed from a chamber of the apparatus at a time distinct from when crystalline biomolecules are removed from another chamber of the apparatus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2021
From: SHARNEZ, RIZWAN; TRIEU, WILLIAM; CAPORINI, MARC A.; KELLY, RON C.; BURT, NEILL; NICHOLSON, LAURA; CHRISTIAN, TWINKLE R.
To: AMGEN INC.
Reel/Frame 056655/0905 →
Continuity (3)
Provisional Application 62476359 · Mar 24, 2017
Provisional Application 62471358 · Mar 14, 2017
Related Publication 20200157141A1 · May 21, 2020